LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

AI-Enabled Diagnostic Testing Could Become More Accurate and Reliable than Current Tests

By LabMedica International staff writers
Posted on 07 Nov 2022
Print article
Image: Numares AXINON System (Photo courtesy of Numares)
Image: Numares AXINON System (Photo courtesy of Numares)

An expanded collaboration between two industry leaders will pave the way for the development of AI-enabled diagnostic testing that is more accurate and reliable than current U.S. tests for patients with chronic diseases, including kidney, cardiovascular, liver and neurologic conditions.

The expanded collaboration builds on Mayo Clinic’s (Rochester, MN, USA) clinical research support for Numares Health (Regensburg, Germany) to include an innovative convertible equity investment. Numares is a health care company using AI-enabled technology to develop novel diagnostic tests designed to give physicians a better tool to care for their patients with conditions related to metabolic dysfunction, such as chronic kidney, liver and cardiac diseases. These assessments also may allow for early intervention to slow disease progression. Enabled by machine learning, this innovative testing modality being researched uses distinct and transparent algorithms combining multiple biomarkers to measure disease progression more accurately in patients with chronic diseases.

Numares develops advanced tests to aid in diagnosis and measurement of disease progression by applying machine learning to metabolomics and other biomarkers. The company has developed the AXINON System that uses next-generation nuclear magnetic resonance spectroscopy to evaluate metabolic constellations and a proprietary magnetic group signaling (MGS) technology that enables the spectroscopy. Two Numares tests are expected to gain FDA 510(k) approval early next year, one assessing kidney function (AXINON GFR(NMR) test) and one measuring cardiac risk (AXINON lipoFIT test).

"The expanded research collaboration and financial investment in Numares will help us further understand this new and potentially disruptive test modality, develop new diagnostic tests and enable Mayo Clinic to better serve our patients and physicians," said Dr. Allan Jaffe, a cardiologist and the former chair of Mayo Clinic's division of clinical core laboratory services in the department of laboratory medicine and pathology.

"This significant expansion of our long-standing collaboration with Mayo Clinic has brought us one step closer to our shared goal of improving patient care," said Winton Gibbons, Numares chief executive officer. "The new investment accelerates our development pipeline and drives research collaborations that fulfill critical unmet medical needs with new clinical utility. With the additional investment, we've enhanced our ability to target our focus on delivering this patient care technology to U.S. physicians as an improved diagnostic tool for their use."

Related Links:
Mayo Clinic 
Numares Health 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more